NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $0.30 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event, filing
TL;DR
NRX Pharma filed an 8-K on 3/5/24, former Big Rock Partners. Details light.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on March 5, 2024, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acquisition Corp. until October 12, 2017, is incorporated in Delaware and headquartered in Wilmington. The filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This filing indicates NRX Pharmaceuticals is making a regulatory submission, which could relate to significant corporate events or financial updates, though details are sparse in this initial report.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of negative financial or operational news.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- October 12, 2017 (date) — Date of name change
- March 5, 2024 (date) — Date of report
- Delaware (location) — State of incorporation
- Wilmington (location) — City of headquarters
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not specify the details of the 'Other Events' reported in the 8-K filing.
What are the key financial statements or exhibits included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but their specific content is not detailed in the provided text.
When did NRX Pharmaceuticals, Inc. change its name from Big Rock Partners Acquisition Corp.?
The company changed its name from Big Rock Partners Acquisition Corp. on October 12, 2017.
What is the business address of NRX Pharmaceuticals, Inc.?
The business address is 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.
What is the Commission File Number for NRX Pharmaceuticals, Inc.?
The Commission File Number for NRX Pharmaceuticals, Inc. is 001-38302.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-06 16:08:01
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
- $0.30 — er share, at a public offering price of $0.30 per share (the " Overallotment Exercise
Filing Documents
- tm248115d1_8k.htm (8-K) — 28KB
- tm248115d1_ex5-1.htm (EX-5.1) — 12KB
- tm248115d1_ex5-1img001.jpg (GRAPHIC) — 4KB
- tm248115d1_ex5-1img002.jpg (GRAPHIC) — 4KB
- 0001104659-24-031475.txt ( ) — 268KB
- nrxp-20240305.xsd (EX-101.SCH) — 3KB
- nrxp-20240305_def.xml (EX-101.DEF) — 26KB
- nrxp-20240305_lab.xml (EX-101.LAB) — 36KB
- nrxp-20240305_pre.xml (EX-101.PRE) — 25KB
- tm248115d1_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On March 5, 2024, the underwriters of the previously announced underwritten public offering of NRx Pharmaceuticals, Inc. (the " Company ") exercised their option in accordance with the Underwriting Agreement, dated February 27, 2024, by and between the Company and EF Hutton LLC, as representative of the several underwriters named therein, to purchase up to an additional 750,000 shares of the Company's common stock, par value $0.001 per share, at a public offering price of $0.30 per share (the " Overallotment Exercise "). The Overallotment Exercise closed on March 6, 2024. The legal opinion, including the related consent, of Haynes and Boone, LLP relating to the issuance and sale of the Option Shares is filed as Exhibit 5.1 hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Haynes and Boone, LLP 23.1 Consent of Haynes and Boone, LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: March 6, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Acting General Counsel